Recormon (epoetin beta)
Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.
Recormon (in some countries NeoRecormon) is a medicine that stimulates red-blood-cell growth. The active substance in Recormon, epoetin beta, is a copy of a human hormone called erythropoietin. Erythropoietin is produced by the kidneys and stimulates the production of red blood cells from the bone marrow. In patients receiving chemotherapy or with chronic renal failure, anaemia can be caused by a lack of erythropoietin, or by the body not responding enough to the erythropoietin it has naturally. The epoetin beta in Recormon works in the body in the same way as the natural hormone to stimulate red blood cell production.1
In Bangladesh Recormon is approved for the following indications.2
- Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in patients on dialysis.
- Treatment of symptomatic renal anaemia in patients not yet undergoing dialysis.
- Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.
- Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.
- Increasing the yield of autologous blood from patients in a pre-donation programme.
Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/L], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Recormon is available as
- Recormon 2,000 IU
- Recormon 5,000 IU
- Recormon 10,000 IU
1. NeoRecormon | European Medicines Agency. [Internet; cited 2018, November 12]. Retrieved from https://www.ema.europa.eu/medicines/human/EPAR/neorecormon
2. Recormon-Product-Information-BD-Ro-205-3859-July 2022